New pangenome project will create a collection of sequences that will provide unique and essential insights into the natural genetic diversity of cannabis.
The analyzer is a hybrid testing machine which combines the use of near-infrared spectroscopy technology with visual image analysis and machine learning to accurately characterize the potency of a cannabis sample.
A list of the proposed rule changes is expected to be published on or after October 31 2018 and will address issues like THC serving limits, packaging requirements, and contaminant testing.
A team at Medicinal Genomics have successfully sequenced the cannabis genome at 640kb N50, representing a 28% improvement on the Human Genome Project standard.
According to statistics provided by California’s Bureau of Cannabis Control, 20% of all cannabis products analyzed by August 6, 2018, received a failed certificate of analysis.
The first voluntary product recall in California was initiated by the vape cartridge manufacturer, The Bloom Brand, on July 25 and the second by Lowell Herb Co. concerning a batch of their pre-rolled cannabis cigarettes.
Across four distinct strains it was observed that the flower samples taken from the upper third of the plant had a higher THC content than those at the base of the plant, and in two of the strains tested the difference was equivalent to the upper flowers being around twice as potent as the lower flowers.
As tighter regulations mandate more rigorous testing, cannabis labs in California must plan and adapt to keep up with the huge influx of samples.
CPC extracts products with nearly 100 percent purity at a 95 percent recovery rate and as such could be used to research, develop and produce cannabis-derived medicines.